Weekly roundup: Another busy week in biopharma

/in

Cycuria Therapeutics launched with a distinguished advisory board and significant public grant funding

Cycuria Therapeutics launched, announcing a distinguished Advisory Board and the successful approval of grant funding from two leading Austrian national funding organisations. Cycuria is developing a first-in-class, protein-based therapy with a differentiated dual-mechanism for hard-to-treat blood cancers, including acute myeloid leukaemia (AML).

Novo Nordisk Foundation expands its Challenge Programme outside of Denmark for the first time and significantly increases grants

The Novo Nordisk Foundation announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK, to lead collaborations applying for grants to study four major themes. This year, the budget for each grant has been increased by 25% to up to DKK 75 million (€10 million) over six years, bringing the overall budget to DKK 600 million (€80 million).

Domain Therapeutics presents novel data at AACR 2025

Domain Therapeutics, the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, announced new clinical and preclinical data for its key oncology programmes DT-9081 and DT-7012, and preclinical insights on its PAR2 biased NAM programme at the American Association for Cancer Research (AACR) in Chicago, USA.

🔥Hot topic

 

👥 Industry events

It was another successful conference by LSX earlier this week. Wonderful to connect with so many of our fantastic industry peers and see our clients Akribion Therapeutics, AstronauTx, Blue Cell Therapeutics, Freya Biosciences, Hansa Biopharma, iOnctura, Novo Holdings, Poolbeg Pharma, Sofinnova Partners and Xeltis participate on thought leadership panels and presentations.

🌟 Industry awards

Congratulations to Optimum clients Ali Tavassoli, Curve Therapeutics, and John Maher, Chief Scientific Officer at Leucid Bio, on their inclusion in The Medicine Maker 2025 Power List!

A fantastic achievement as they are recognised for helping to advance innovation in drug development, see the full list here.

Sector moves

Keep up to date with the latest industry moves here.

That’s all folks!  To stay in the know – subscribe to Optimum’s weekly wrap-up today!